About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Tarsus Pharmaceuticals, Inc. (TARS): Insider Trades and Fund Holdings
In the past 12 months, Tarsus Pharmaceuticals, Inc. insiders reported no open-market purchases and 13 sales worth $7.65M; 12 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Sep 15, 2026Insider saleDirector William J. Phd Link sold $979,745 under a 10b5-1 plan (5 days after: completed an acquisition or sale of assets)
- Sep 15, 2026Planned saleWILLIAM J LINK (director) filed notice to sell about $979,745 around Sep 15, 2026
- Sep 10, 2026NewsCompany reported: Completed an acquisition or sale of assets
- Sep 4, 2026Insider saleChief Medical Officer Elizabeth Yeu Lin sold $1.2 million under a 10b5-1 plan
- Sep 4, 2026Insider saleCEO Bobak R. Azamian sold $905,600 under a 10b5-1 plan
- Sep 4, 2026Insider saleCOO Seshadri Neervannan sold $387,940 under a 10b5-1 plan
- Sep 4, 2026Planned saleLin Elizabeth Yeu (officer) filed notice to sell about $942,635 around Sep 4, 2026
- Sep 4, 2026Planned saleBOBAK AZAMIAN (officer) filed notice to sell about $905,587 around Sep 4, 2026
- Sep 4, 2026Planned saleNeervannan Seshadri (officer) filed notice to sell about $387,940 around Sep 4, 2026
- Sep 4, 2026Planned saleLin Elizabeth Yeu (member of immediate family of any of the foregoing) filed notice to sell about $278,250 around Sep 4, 2026
- Sep 2, 2026Insider saleCEO Bobak R. Azamian sold $800,600 under a 10b5-1 plan
- Sep 2, 2026Insider saleChief Medical Officer Elizabeth Yeu Lin sold $558,160 under a 10b5-1 plan
- Sep 2, 2026Planned saleBOBAK AZAMIAN (officer) filed notice to sell about $800,569 around Sep 2, 2026
- Sep 2, 2026Planned saleMottiwala Aziz (former officer) filed notice to sell about $654,373 around Sep 2, 2026
- Sep 2, 2026Planned saleLin Elizabeth Yeu (officer) filed notice to sell about $430,960 around Sep 2, 2026
- Sep 2, 2026Planned saleLin Elizabeth Yeu (member of immediate family of any of the foregoing) filed notice to sell about $127,200 around Sep 2, 2026
- Sep 1, 2026Insider saleChief Medical Officer Elizabeth Yeu Lin sold $339,830 under a 10b5-1 plan
- Sep 1, 2026Planned saleMottiwala Aziz (former officer) filed notice to sell about $5.7 million around Sep 1, 2026
- Sep 1, 2026Planned saleLin Elizabeth Yeu (officer) filed notice to sell about $339,830 around Sep 1, 2026
- Aug 25, 2026Planned saleMottiwala Aziz (former officer) filed notice to sell about $5.8 million around Aug 25, 2026
- Aug 19, 2026Planned saleMottiwala Aziz (former officer) filed notice to sell about $3.8 million around Aug 19, 2026
- Jun 30, 2026FundRenaissance Technologies cut 87% in Q2 2026 (13F filed Aug 13, 2026)
- Jun 17, 2026Insider saleCEO Bobak R. Azamian sold $615,489 under a 10b5-1 plan
- Jun 16, 2026Insider saleSee Remarks Jeffrey S. Farrow sold $877,436
- Jun 15, 2026Insider saleDirector William J. Phd Link sold $776,495 under a 10b5-1 plan
- Jun 15, 2026Insider saleDirector Katherine Goodrich sold $183,384 under a 10b5-1 plan
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 17, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 17 | William J. Phd LinkDirector | ▼ SELL10b5-1 | $980K |
| Sep 9 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $943K |
| Sep 9 | Bobak R. AzamianCEO | ▼ SELL10b5-1 | $906K |
| Sep 9 | Seshadri NeervannanCOO | ▼ SELL10b5-1 | $388K |
| Sep 9 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $278K |
| Sep 3 | Bobak R. AzamianCEO | ▼ SELL10b5-1 | $801K |
| Sep 3 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $431K |
| Sep 3 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $340K |
| Sep 3 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $127K |
| Jun 22 | Bobak R. AzamianCEO | ▼ SELL10b5-1 | $615K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| William J. Phd Link | Director | 0 | $0 | 2 | $1.76M |
| Elizabeth Yeu Lin | Chief Medical Officer | 0 | $0 | 5 | $2.12M |
| Bobak R. Azamian | CEO | 0 | $0 | 3 | $2.32M |
| Seshadri Neervannan | COO | 0 | $0 | 1 | $388K |
| Jeffrey S. Farrow | See Remarks | 0 | $0 | 1 | $877K |
| Katherine Goodrich | Director | 0 | $0 | 1 | $183K |
Buybacks and executive pay
| Year | CEO pay reported | CEO pay "actually paid" | Value of $100 invested |
|---|---|---|---|
| 2025 | $6.62M | $31.1M | n/a |
| 2024 | $7.90M | $19.8M | n/a |
| 2023 | $3.13M | $4.50M | n/a |
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
A All 13 insider trades reported on time. How it is graded
Tracked funds that report TARS
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 9,300 | $585K | ▼ −87.3% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →